Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARINER
2014-000305-13Phase 3Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in venous thromboembolism (VTE) comparing Rivaroxaban with Placebo (2 arms). Primary endpoint: Time from randomization to first symptomatic venous thromboembolism event or venous thromboembolism-related death. Started May 2014; status: terminated.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2014-000305-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000305-13.